Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug

Bristol-Myers Squibb. "Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma." Bayer. "OCEANIC-AF study stopped early due to lack of efficacy." Key Takeaways - Bristol-Myers Squibb and 2seventy bio shares dropped after the FDA said it would not make a decision on expanded use of the companies' cancer drug next month. - The treatment has already been approved by regulators to treat adults who haven't responded to other medicines. - A decision by …